Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


A Responsible Choice

New demands in R+D centers are related to scale-up feasibility and quality of procedures and research methods. FDA investigators consider that transfer of technology from R+D departments to clinical trials and later commercial production is carried out with lack of strictness and poor documentation practices. Therefore, they are emphasizing on the concept of cGMP as a quality oversight, comprising all practices in R+D and production processes.

The new LyoBeta Serieslyophilizers are laboratory units that have been designed specifically for advanced research centers, keeping in mind that initial development of new drugs is one of the most critical issues for their final commercial success.